Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

Conditions: Cardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy Interventions: Other: Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines; Other: Standard of Care (SoC) dosing of atorvastatin; Other: Standard of Care (SoC) dosing of simvastatin; Other: Standard of Care (SoC) dosing of pitavastatin; Other: Standard of Care (SoC) dosing of rosuvastatin; Other: Standard of Care (SoC) dosing of prasavastatin; Other: Standard of Care (SoC) dosing of lovastatin; Other: Standard of Care (SoC) dosing of fluvastatin Sponsors: Instituto de Investigaci ón Hospital Universitario La Paz; Instituto de Salud Carlos III Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials